AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions Posted on October 26, 2024 by admin Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.